rs1004819 — IL23R

Intronic IL-23 receptor variant that increases susceptibility to ankylosing spondylitis and inflammatory bowel disease by enhancing IL-23/Th17 inflammatory signaling

See your personal result for IL23R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL23R rs1004819 — A Key Risk Switch for Ankylosing Spondylitis and Crohn's Disease

Your immune system constantly patrols for threats, and a cytokine called interleukin-23 (IL-23)11 interleukin-23 (IL-23)
a signaling protein that activates inflammatory immune cells sits at the center of that patrol. IL-23 works by binding to the IL-23 receptor (IL23R), triggering the differentiation of [Th17 cells | a class of T helper cells that drive chronic inflammation at barrier surfaces like the gut and joints]. rs1004819 is an intronic variant in IL23R that tags a disease-associated haplotype repeatedly found at elevated frequencies in people with ankylosing spondylitis (AS) and inflammatory bowel disease (IBD). Unlike the nearby rs11209026 R381Q variant — which changes the receptor protein itself — rs1004819 influences gene regulation, making it a marker of a distinct functional haplotype in the same gene.

The Mechanism

rs1004819 sits within an intron of IL23R on chromosome 1 (GRCh38 position 67,204,530). As an [intronic variant | a change within a non-coding section of the gene, between exons], it does not alter the amino acid sequence of the IL-23 receptor protein. Instead, it likely acts as a [regulatory or haplotype-tagging variant | marking a set of co-inherited alleles that affect IL23R expression levels or splicing efficiency]. The IL23R gene spans a complex region with multiple independently associated loci; rs1004819 tags a distinct linkage disequilibrium block from the well-characterized R381Q variant (rs11209026), meaning it captures a different source of inherited IL-23 signaling variation.

Functionally, variants in this haplotype block are thought to modestly upregulate IL-23 receptor expression or enhance downstream signaling efficiency. The net effect is a heightened IL-23/Th17 axis response — stronger inflammatory reactions to microbial triggers at the gut epithelium and in the entheses (tendon-bone attachment points) of the spine and sacroiliac joints. This fits the known biology: Th17 cells are the dominant inflammatory cell type in both AS and IBD, and IL-23 blockade is now a validated therapeutic strategy for both conditions.

The Evidence

The most comprehensive IBD evidence comes from Glas et al. 200722 Glas et al. 2007
rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients, which screened 2,670 individuals (833 CD, 456 UC, 1,381 controls) across the entire IL23R gene. rs1004819 was the top hit: OR 1.56 (95% CI 1.37-1.78), p = 1.92×10⁻¹¹. Strikingly, 93.2% of homozygous risk carriers (AA genotype) had ileal involvement in their Crohn's disease, compared to 78% of GG carriers, suggesting that beyond susceptibility this variant shapes disease location. This association was independently replicated in Korean CD patients33 Korean CD patients
Yang et al. 2009, aOR 1.82, p=0.009 and in multiple European cohorts.

For ankylosing spondylitis, Zhong et al. 201844 Zhong et al. 2018
Complex role of IL-23R polymorphisms on ankylosing spondylitis: a meta-analysis pooled 25 case-control studies comprising 8,431 AS cases and 8,972 controls. The A allele at rs1004819 was significantly more frequent in AS cases than controls (p<0.001), making it one of three IL23R variants confirmed to increase AS susceptibility in this meta-analysis. Additional AS support comes from Pimentel-Santos et al. 200955 Pimentel-Santos et al. 2009
OR 1.4, p=0.0049 in Portuguese AS patients, and from Ruyssen-Witrand et al. 201966 Ruyssen-Witrand et al. 2019
DESIR cohort, 645 early axSpA patients, where rs1004819 was the only IL23R polymorphism significantly associated with active sacroiliac joint inflammation on MRI (p=0.0005).

The evidence for IBD is stronger (larger studies, lower p-values) than for AS, where individual studies are smaller. However, the consistent direction across multiple populations and the confirmatory meta-analysis establish this as a genuine AS susceptibility locus. Evidence level is rated strong based on multi-cohort replication and a formal meta-analysis.

Practical Implications

Carrying one or two copies of the A allele at rs1004819 modestly increases your baseline risk for Crohn's disease and ankylosing spondylitis. "Modestly" is key — the odds ratios (~1.4-1.6 per allele) translate to a meaningful but not dramatic absolute risk increase, and the majority of A allele carriers never develop either condition. Environmental factors, other genetic variants, and lifestyle all interact with this predisposition.

For gut health, the ileal involvement signal in Crohn's disease is notable: if you do develop CD, carriers of the A allele are more likely to have inflammation in the ileum (the last section of the small intestine) rather than just the colon. This matters for clinical monitoring — ileal disease often presents differently and has different complications than colonic disease. Maintaining a diverse gut microbiome through high-fiber diets, avoiding unnecessary antibiotics, and not smoking (a major CD risk factor) may reduce the chance that genetic predisposition translates into active disease.

For joint and spine health, the AS connection means paying attention to early warning signs: inflammatory back pain (worse at rest, better with movement), morning stiffness lasting more than 30 minutes, buttock pain that alternates sides. Early diagnosis of axial spondyloarthritis allows earlier treatment, and IL-23 targeted biologics (risankizumab, guselkumab) are now available for AS — you carry the genetic variant that these drugs effectively counteract.

IL-23 targeted therapies — including ustekinumab (anti-IL-12/23), risankizumab (anti-IL-23), and guselkumab — are approved for both Crohn's disease and AS. Carriers of the A allele at rs1004819 are, in biological terms, people whose disease is driven by an overactive IL-23 axis, making them plausible preferential responders to this drug class.

Interactions

rs1004819 occupies a distinct linkage disequilibrium block from the other major IL23R variant in this database, rs11209026 (R381Q). The R381Q variant is a loss-of-function coding change that is strongly protective against IBD and AS; rs1004819 is a risk-tagging intronic variant. These two signals are largely independent — inheriting one does not preclude the other — and can be thought of as operating on different levers of IL-23R function (protein activity vs. expression/regulation).

rs2201841, another IL23R intronic variant in the database, is also associated with AS and IBD. It resides in a different LD block from rs1004819 and may independently tag the same or an overlapping disease-associated haplotype. Individuals carrying risk alleles at both rs1004819 and rs2201841 may have additive susceptibility, though formal interaction analysis has not been published. The overall IL23R locus contributes substantially to AS and IBD genetic architecture through at least these two independent intronic signals plus the R381Q coding variant.

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard Risk Normal

Standard IL-23 receptor signaling — baseline risk for inflammatory diseases

You carry two copies of the G allele at rs1004819, the most common genotype in European populations (about 49% of people). This represents the reference genotype with standard IL-23 receptor expression and function. Your genetic risk for ankylosing spondylitis and Crohn's disease from this particular variant is at baseline — neither elevated nor reduced. Most people with GG never develop either condition. Other genetic, environmental, and lifestyle factors will shape your actual inflammatory disease risk.

AG Elevated Risk High Risk

One copy of the risk allele — moderately increased susceptibility to AS and IBD

The heterozygous AG genotype gives you one copy of the disease-risk haplotype tagged by the A allele. The IL23R locus mediates the magnitude of Th17-driven inflammation in the gut and at entheses (tendon-bone junctions in the spine and sacroiliac joints). Elevated IL-23 signaling from this haplotype creates a lower threshold for triggering the chronic inflammatory cascades that underlie both IBD and spondyloarthritis.

Notably, in Crohn's disease studies, risk allele carriers are more likely to have ileal (small intestine) disease involvement, which tends to have a different clinical presentation and complication profile than colonic disease alone. Early vigilance for gut symptoms — persistent diarrhea, cramping, unintended weight loss, blood in stool — can enable earlier diagnosis and intervention.

For AS, the connection to sacroiliac MRI inflammation is particularly noteworthy: a 2019 study of 645 early-onset axial spondyloarthritis patients found rs1004819 was the only IL23R polymorphism significantly associated with active sacroiliac joint inflammation visible on MRI, suggesting this variant particularly influences the early inflammatory phase of the disease.

AA Highest Risk High Risk

Two copies of the risk allele — highest genetic susceptibility to AS and IBD from this variant

The AA homozygous genotype at rs1004819 represents the highest-risk state from this IL23R locus. With two copies of the disease-associated haplotype, IL-23 receptor activity is likely at its most elevated, creating the strongest genetic predisposition to Th17-driven inflammation among the three possible genotypes.

The ileal involvement data from Glas et al. 2007 is striking: 93.2% of AA homozygotes with Crohn's disease had ileal involvement, compared to 78% of GG carriers. Ileal Crohn's disease carries higher risk of stricture formation, fistulas, and bowel obstruction than colonic disease. This makes proactive monitoring and early treatment engagement particularly important for AA carriers who develop IBD.

For ankylosing spondylitis, homozygosity for the risk haplotype likely creates stronger inflammatory drive at the sacroiliac joints and spine. IL-23-targeted biologics (risankizumab, guselkumab) are now approved for both AS and Crohn's disease and represent particularly well-matched therapies for individuals whose disease is genetically linked to an overactive IL-23 axis.

Carrying this genotype does not mean disease is inevitable — most AA carriers do not develop AS or IBD. But the genetic signal is robust enough to warrant proactive awareness and early evaluation of relevant symptoms.